AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) saw unusually-strong trading volume on Friday . Approximately 2,293,301 shares changed hands during trading, an increase of 111% from the previous session’s volume of 1,088,499 shares.The stock last traded at $14.45 and had previously closed at $14.45.

A number of equities analysts have commented on AMAG shares. Jefferies Group reaffirmed a “buy” rating and set a $16.00 target price on shares of AMAG Pharmaceuticals in a research note on Sunday, November 5th. Zacks Investment Research raised shares of AMAG Pharmaceuticals from a “hold” rating to a “buy” rating and set a $21.00 target price on the stock in a research note on Wednesday, October 4th. Janney Montgomery Scott reissued a “hold” rating on shares of AMAG Pharmaceuticals in a research note on Tuesday, October 17th. Cantor Fitzgerald reissued a “hold” rating and issued a $21.00 price target on shares of AMAG Pharmaceuticals in a research note on Thursday, September 28th. Finally, Deutsche Bank reissued a “hold” rating and issued a $24.00 price target on shares of AMAG Pharmaceuticals in a research note on Thursday, August 31st. Two investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and three have assigned a buy rating to the stock. AMAG Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $23.38.

The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.48 and a current ratio of 1.59.

Several institutional investors have recently added to or reduced their stakes in AMAG. Municipal Employees Retirement System of Michigan grew its holdings in shares of AMAG Pharmaceuticals by 6.6% in the second quarter. Municipal Employees Retirement System of Michigan now owns 8,280 shares of the specialty pharmaceutical company’s stock valued at $152,000 after purchasing an additional 510 shares in the last quarter. Hartford Investment Management Co. acquired a new position in shares of AMAG Pharmaceuticals in the third quarter valued at approximately $186,000. 361 Capital LLC acquired a new position in shares of AMAG Pharmaceuticals in the third quarter valued at approximately $197,000. Cubist Systematic Strategies LLC acquired a new position in shares of AMAG Pharmaceuticals in the third quarter valued at approximately $197,000. Finally, Aperio Group LLC acquired a new position in shares of AMAG Pharmaceuticals in the third quarter valued at approximately $198,000.

COPYRIGHT VIOLATION NOTICE: “AMAG Pharmaceuticals (AMAG) Sees Strong Trading Volume” was first reported by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another domain, it was stolen and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.watchlistnews.com/amag-pharmaceuticals-amag-sees-strong-trading-volume/1766674.html.

About AMAG Pharmaceuticals

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.